At the time of writing, Spyre Therapeutics Inc. [SYRE] stock is trading at $28.75, up 2.42%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SYRE shares have gain 12.61% over the last week, with a monthly amount glided 6.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Robert W. Baird started tracking the stock with Outperform rating on May 02, 2024, and set its price target to $50. On March 01, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $35 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $32 on December 20, 2023. Jefferies initiated its recommendation with a Buy and recommended $31 as its price target on December 11, 2023. Guggenheim started tracking with a Buy rating for this stock on December 11, 2023, and assigned it a price target of $44. In a note dated May 04, 2020, Piper Sandler initiated an Overweight rating and provided a target price of $12 on this stock.
For the past year, the stock price of Spyre Therapeutics Inc. fluctuated between $8.43 and $47.97. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Spyre Therapeutics Inc. [NASDAQ: SYRE] shares were valued at $28.75 at the most recent close of the market. An investor can expect a potential return of 39.13% based on the average SYRE price forecast.
Analyzing the SYRE fundamentals
According to Spyre Therapeutics Inc. [NASDAQ:SYRE], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.07% with Operating Profit Margin at -149.88%, Pretax Profit Margin comes in at -178.45%, and Net Profit Margin reading is -178.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -1.6 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.27 points at the first support level, and at 27.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.11, and for the 2nd resistance point, it is at 29.48.
Ratios To Look Out For
It is important to note that Spyre Therapeutics Inc. [NASDAQ:SYRE] has a current ratio of 19.70. As well, the Quick Ratio is 19.70, while the Cash Ratio is 2.04.
